8-K: Heron Therapeutics Q3 2025 Revenue Jumps, Reaffirms Guidance

Heron Therapeutics announced strong Q3 2025 revenue growth for its Acute Care franchise, driven by ZYNRELEF and APONVIE, while reaffirming full-year financial guidance.

Summary

• Generated Q3 2025 Net Revenue of $38.2 million, an increase of 16.5% compared to Q3 2024.
• Year-to-date Net Revenue reached $114.3 million, up 10.4% from the same period in 2024.
• Reaffirmed 2025 full-year Net Revenue Guidance of $153 million $163 million.
• Reaffirmed 2025 full-year Adjusted EBITDA Guidance of $9.0 million $13.0 million, an increase from the original Q1 guidance of $0 $8.0 million.
• ZYNRELEF Net Revenue grew 49% in Q3 2025 compared to Q3 2024, reaching $9.3 million.
• APONVIE Net Revenue grew 173% in Q3 2025 compared to Q3 2024, reaching $3.0 million.
• The Acute Care franchise delivered revenue growth of 67.2% year-over-year in Q3 2025 and 69.2% year-over-year for the first nine months of 2025.
• CINVANTI unit demand and Net Revenue increased 6% in Q3 2025 compared to Q3 2024.
• Cash, cash equivalents, and short-term investments totaled $55.5 million as of September 30, 2025.
• Reported a net loss of $(17.495) million for Q3 2025, compared to a net loss of $(4.848) million for Q3 2024.
• Adjusted EBITDA for Q3 2025 was $1.542 million, compared to $(0.355) million for Q3 2024.
• Incurred a loss on debt extinguishment of $(11.339) million in Q3 2025.

Sentiment

Score: 7

Explanation: While the company reported a significant net loss due to a one-time debt extinguishment, the core business performance, particularly the Acute Care franchise, showed strong revenue growth. The reaffirmation of full-year guidance, including an improved Adjusted EBITDA outlook, indicates positive operational momentum despite the financial restructuring impact.

Positives

• Acute Care franchise revenue grew significantly by 67.2% in Q3 2025 and 69.2% year-to-date, indicating strong commercial acceleration.
• ZYNRELEF Net Revenue increased 49% in Q3 2025, driven by the successful launch of the Vial Access Needle (VAN) and enhanced distributor incentive programs.
• APONVIE Net Revenue surged by 173% in Q3 2025, supported by increased adoption and the momentum from a newly launched dedicated sales team.
• CINVANTI maintained consistent performance with a 6% increase in unit demand and Net Revenue in Q3 2025.
• Reaffirmed 2025 full-year Net Revenue guidance and increased the lower end of the Adjusted EBITDA guidance, reflecting confidence in future performance.
• The permanent, product-specific J-code for ZYNRELEF went live on October 1, 2025, which is expected to streamline reimbursement and improve billing clarity.
• Achieved positive Adjusted EBITDA of $1.542 million in Q3 2025, a significant improvement from a negative Adjusted EBITDA in Q3 2024.

Negatives

• Reported a substantial net loss of $(17.495) million in Q3 2025, significantly wider than the $(4.848) million loss in Q3 2024.
• Incurred a one-time loss on debt extinguishment of $(11.339) million in Q3 2025.
• SUSTOL Net Revenue decreased by 30.8% in Q3 2025 and 32.5% year-to-date, indicating declining performance for this product.
• Overall Oncology segment revenue decreased by 3.4% year-to-date, primarily due to the decline in SUSTOL.

Risks

• Potential market opportunities for ZYNRELEF, APONVIE, CINVANTI, and SUSTOL may not materialize as expected.
• Interim financial data or prescription data may not be indicative of quarterly or annual results.
• Ability to establish and maintain successful commercial arrangements, such as co-promotion agreements, may be challenging.
• The outcome of pending patent litigations, including potential appeals of any verdicts and settlements, could negatively impact the company.
• There is a risk that the company may be required to write-off additional inventory in the future.
• The expected future balances of cash, cash equivalents, and short-term investments may not be sufficient to fund operations for the anticipated duration.
• Future equity financings may be needed, which could dilute existing shareholders.
• The terms and conditions, completion, anticipated proceeds, and use of proceeds of refinancing transactions carry inherent risks.
• Inability or delay in achieving profitability could occur due to regulatory developments and policy changes in the U.S. and other jurisdictions.

Future Outlook

Heron Therapeutics reaffirmed its full-year 2025 Net Revenue guidance of $153 million to $163 million and Adjusted EBITDA guidance of $9.0 million to $13.0 million. The ZYNRELEF Prefilled Syringe program is progressing with stability studies commenced, and approval is anticipated in 2027 if successful. The company expects continued positive impact from new commercial initiatives, including the dedicated ZYNRELEF sales team, enhanced distributor incentives, and the APONVIE team leveraging resources to drive adoption.

Management Comments

• "There were a number of new initiatives launched in the third quarter, and were encouraged by the early signs that theyre positively impacting our commercial execution and driving increased demand for our products." Craig Collard, Chief Executive Officer.

Industry Context

Heron Therapeutics operates in the biotechnology sector, with a focus on acute care (postoperative pain and PONV) and oncology (CINV prevention). The strong growth in ZYNRELEF and APONVIE suggests successful commercialization efforts in the acute care segment, which is a competitive but high-demand area. The emphasis on new sales teams and enhanced distributor incentives reflects common strategies in the pharmaceutical industry to drive product adoption and market share. While the oncology segment shows stability for CINVANTI, the decline in SUSTOL indicates a potential shift in market dynamics or product focus within their portfolio.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to global benchmarks, making a direct assessment against industry standards challenging based solely on the provided information.

Legal Proceedings

• The company's forward-looking statements mention 'the outcome of the Company's pending patent litigations, including potential appeals of any verdicts and the settlement described herein', indicating ongoing legal matters, but no specific updates or details are provided in this filing.

Stakeholder Impact

• Shareholders: Potential for increased value due to strong product growth and reaffirmed guidance, but diluted by net loss and the explicit mention of potential future equity financings.
• Customers (Hospitals/ASCs): Benefit from enhanced ZYNRELEF device (VAN) and streamlined reimbursement (J-code), potentially leading to broader product adoption.
• Employees: New dedicated sales teams for ZYNRELEF and APONVIE indicate continued investment in commercial operations and potential job stability/growth in those areas.
• Creditors: Debt refinancing transactions have occurred, impacting the company's debt structure and potentially its credit profile.

Next Steps

• Continue to drive commercial execution and increase demand for products through new initiatives.
• Progress the ZYNRELEF Prefilled Syringe program, with anticipated approval in 2027 if stability studies are successful.
• Leverage the permanent J-code for ZYNRELEF to streamline reimbursement and improve billing clarity.
• Host a conference call and live webcast on November 4, 2025, to discuss the financial results and corporate updates.

Key Dates

Recommendation

The company demonstrates strong operational growth in its key Acute Care products (ZYNRELEF and APONVIE) and has reaffirmed its full-year guidance, which is a positive signal. However, the significant net loss in Q3, primarily due to a debt extinguishment, and the explicit mention of potential future equity financings introduce a degree of financial uncertainty. While the operational momentum is encouraging, the financial structure changes and the need for potential future capital raises warrant a cautious 'Hold' stance until further clarity on long-term profitability and financing strategies emerges.

Keywords

Heron Therapeutics, HRTX, Q3 2025, financial results, biotechnology, acute care, oncology, ZYNRELEF, APONVIE, CINVANTI, SUSTOL, revenue growth, adjusted EBITDA, postoperative pain, nausea and vomiting, SEC filing